I have no familiarity with the specific arrangements existing between Cellmid and its licensing partners other than has been released in the relevant ASX announcements or available through passing reference in its various reports. For budding detectives, some clues are available through the ‘licence fees and royalties’ item of financial reports.
I am familiar with the many sources of complexity in IP management and the requirement for confidentiality by both a company and its licensing partner.
Any technical progress or results obtained by a partner become part of its own IP, and there can be no advantage in releasing it, even to the licensing company, unless it has become patent protected. Even indicating whether a program is currently active provides information to a potential competitor.
Cellmid is in a position to provide general updates to shareholders on progress achieved its own product development programs because of the wide patent protection that it holds on the midkine technology.
CDY Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
